Wednesday, July 8, 2026

biotech · Duchenne Muscular Dystrophy · Duchenne muscular dystrophy · SLDB

Solid Biosciences

Solid Biosciences clinical programs — 16 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US HQ
2013 Founded
155 Employees
Public company Type
SLDB · NYSE Ticker
Company details
Status
Public
HQ
500 Rutherford Ave, Third Floor, Boston, Massachusetts 02129, US
Founded
2013
Employees
155
Programs
16
Drugs
20
Patents
2
Intelligence · Clinical Programs

Solid Biosciences projects

16 ClinicalTrials.gov programs sponsored by Solid Biosciences.

Solid Biosciences has 16 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CWS-2007-HR

    Solid Biosciences

    Soft Tissue Sarcoma

    phase 3 small molecule completed

    1 trial
  2. IP

    Solid Biosciences

    Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial
  3. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials
  4. dactinomycin

    Solid Biosciences

    Sarcoma

    phase 3 mab active

    1 trial
  5. filgrastim

    Solid Biosciences

    Ovarian Cancer

    phase 3 mab completed

    1 trial
  6. filgrastim

    Solid Biosciences

    Lung Cancer

    phase 3 mab active

    1 trial
  7. filgrastim

    Solid Biosciences

    Lymphoma

    phase 3 mab active

    2 trials
  8. Bevacizumab/Irinotecan

    Solid Biosciences

    Glioblastoma

    phase 2 small molecule completed

    1 trial
  9. Cetuximab

    Solid Biosciences

    Head and Neck Neoplasm

    phase 2 small molecule completed

    1 trial
  10. Erlotinib

    Solid Biosciences

    Leptomeningeal Carcinomatosis

    phase 2 small molecule terminated

    1 trial
  11. SGT-001

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 2 gene therapy active

    1 trial
  12. SGT-003-101

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial
  13. docetaxel+CDDP

    Solid Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule terminated

    1 trial
  14. genexolPM + cisplatin

    Solid Biosciences

    Locally Advanced Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial
  15. SGT-212

    Solid Biosciences

    Friedreich's Ataxia (FA)

    phase 1 small molecule active

    1 trial
  16. SGT-501

    Solid Biosciences

    Catecholaminergic Polymorphic Ventricular Tachycardia

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Solid Biosciences have?

16 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.